> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cencora Guides Fiscal 2027 Adjusted EPS To $19.40–$19.75 And Lifts Its Dividend 10%
- URL: https://www.bullished.co/cencora-guides-fiscal-2027-adjusted-eps-to-19-40-19-75-and-lifts-its-dividend-10-0e4f0b41/
- Published: 2026-11-04T11:51:14.000Z
- Updated: 2026-11-04T11:51:14.000Z
- Description: The drug distributor also splits its business into new segments, with fourth-quarter adjusted earnings of $4.66 a share, up 21.4%.
- Author: Matteo Parrino
- Tags: Earnings, COR, Industry: Healthcare

[Cencora](https://www.bullished.co/tag/cor/), which distributes pharmaceuticals and healthcare products and provides services to drugmakers, [expects adjusted earnings of $19.40 to $19.75 a share](https://www.sec.gov/Archives/edgar/data/0001140859/000114085926000038/exhibit991-q42026.htm?ref=bullished.co) in fiscal 2027, growth of 8% to 10%, the company said Wednesday. It also raised its quarterly dividend 10% and reorganized its reporting around specialty care.

## A quarter lifted by OneOncology

Fourth-quarter revenue rose 5.5% to $88.4 billion. Adjusted earnings per share climbed 21.4% to $4.66 from $3.84 a year earlier. Standard-accounting earnings were $2.71 a share, against a loss of $1.75 a year earlier, when a $723.9 million goodwill impairment on PharmaLex hit results.

Gross profit rose 21.9%, helped by the February 2026 OneOncology acquisition and partly offset by lower-margin sales of GLP-1 weight-loss and diabetes drugs. For the full year, revenue rose 5.0% to $337.4 billion, standard earnings reached $17.95 a share and adjusted earnings rose 12.3% to $17.97.

The full-year standard figure includes a $1.1 billion gain from remeasuring Cencora's earlier OneOncology investment and extinguishing the related put option liability. Adjusted earnings exclude it.

"Fiscal 2026 was a pivotal year for Cencora," said Robert P. Mauch, president and chief executive.

## The fiscal 2027 outlook

Cencora forecasts revenue growth of 3% to 5%, adjusted operating income growth of 4% to 6% and adjusted free cash flow of about $3.5 billion, down from $3.8 billion in fiscal 2026\. It expects about 190 million diluted shares, against 194.1 million, and net interest expense of $490 million to $510 million.

The outlook assumes the sale of its Profarma stake closes in the first fiscal quarter and that the MWI Animal Health merger with Covetrus closes March 31, 2027.

## New segments and a bigger oncology bet

Starting in the first quarter of fiscal 2027, Cencora will report Pharmaceutical Distribution and Services and Specialty Pharmaceutical and Provider Services, replacing its U.S. and International segments. It forecasts specialty operating income growth of 18% to 21% next year, against 2% to 4% for distribution. Long-term targets are mid-teens growth for specialty and mid-single digits for distribution.

The company also signed a deal to buy American Oncology Network, a network of more than 350 oncology providers across 21 states.

The board declared a quarterly dividend of $0.66 a share, up from $0.60, payable November 30 to holders of record on November 13.

Management discusses the results on a call at 8:30 a.m. ET Wednesday, and the first report under the new segments comes with the first quarter of fiscal 2027.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Cencora, Inc. (COR)](https://www.sec.gov/Archives/edgar/data/0001140859/000114085926000038/abc-20261104.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exhibit991-q42026.htm — Cencora, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001140859/000114085926000038/exhibit991-q42026.htm?ref=bullished.co) — SEC EDGAR

### More on Cencora

- [Cencora Agrees To Buy American Oncology Network In $2.4 Billion Enterprise-Value Deal](https://www.bullished.co/cencora-agrees-to-buy-american-oncology-network-in-2-4-billion-enterprise-value-deal-72d7f316/)

[All Cencora (COR) coverage →](https://www.bullished.co/tag/cor/)